Acute Biphenotypic Leukemia — Trials

Acute Biphenotypic Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

41 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 14%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03404193	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome	terminated	Phase 2	235	M.D. Anderson Cancer CenterOTHER	1	Mar 10, 2026	clinicaltrials
NCT04874194	Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1	terminated	Phase 1 / Phase 2	24	M.D. Anderson Cancer CenterOTHER	1	Nov 3, 2025